Bayer’s Stivarga is being backed by the National Institute for Health and Care Excellence as a cost-effective option for the treatment of adults with gastrointestinal stromal tumours (GIST). More: NICE backing for Bayer’s Stivarga in GIST Source: News
read moreMore than 90 percent of health and care leaders across England say they are “concerned” about their organisation’s ability to cope with demand this winter, with the majority (63 percent) citing “extreme” concern. More: Health and care leaders fear winter
read moreMSD has decided to pull the plug on its late-stage cholesterol drug anacetrapib after a review of clinical data. More: MSD pulls plug on cholesterol drug anacetrapib Source: News
read moreHaving recently completed an expansion in Hungary, anti-infectives specialist Xellia Pharmaceuticals is moving on to a project at its headquarters site in Denmark. More: Xellia bolsters sterile production at Denmark site Source: fierce
read moreCalifornia’s new pricing law won’t take effect until 2018, but one analyst believes the cascade of disclosures after that could have widespread effects throughout pharma, including new de facto limits on price increases. More: Will 5% be the next price-hike
read moreScott Gottlieb might be a potential replacement for former HHS secretary Tom Price, but the FDA commissioner says he’d rather stay put—and pharma may prefer the same thing, given industry response to changes he’s made since taking the helm. More:
read more© 1994 - 2026 B.M. Pharmaceuticals